Cardax Inc. (CDXI)
| Market Cap | 1.39M |
| Revenue (ttm) | 538,946 |
| Net Income (ttm) | -5.06M |
| Shares Out | 794,183 |
| EPS (ttm) | -6.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $1.75 |
| Previous Close | $1.75 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 1.75 |
| Day's Range | 1.75 - 1.75 |
| Day's Volume | 0 |
| 52-Week Range | 1.15 - 9.80 |
News
There are no news available yet.
About CDXI
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a targ... [Read more...]
| Industry Biotechnology | |
| Stock Exchange OTCMKTS | Ticker Symbol CDXI |
Financial Performance
In 2020, Cardax's revenue was $538,946, a decrease of -24.19% compared to the previous year's $710,949. Losses were -$5.06 million, -0.74% less than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for Cardax is 1.00, which is a decrease of -42.86% from the latest price.